CA2964378A1 - Promoting epithelial regeneration post tonsillectomy using heparin binding epidermal growth factor like growth factor - Google Patents

Promoting epithelial regeneration post tonsillectomy using heparin binding epidermal growth factor like growth factor Download PDF

Info

Publication number
CA2964378A1
CA2964378A1 CA2964378A CA2964378A CA2964378A1 CA 2964378 A1 CA2964378 A1 CA 2964378A1 CA 2964378 A CA2964378 A CA 2964378A CA 2964378 A CA2964378 A CA 2964378A CA 2964378 A1 CA2964378 A1 CA 2964378A1
Authority
CA
Canada
Prior art keywords
egf
composition
administered
tonsillectomy
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2964378A
Other languages
English (en)
French (fr)
Inventor
Peter Luke Santa Maria
Chloe DOMVILLE-LEWIS
Daniel BESWICK
Robson CAPASSO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CA2964378A1 publication Critical patent/CA2964378A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2964378A 2014-10-21 2015-10-21 Promoting epithelial regeneration post tonsillectomy using heparin binding epidermal growth factor like growth factor Abandoned CA2964378A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462066564P 2014-10-21 2014-10-21
US62/066,564 2014-10-21
PCT/US2015/056651 WO2016064998A1 (en) 2014-10-21 2015-10-21 Promoting epithelial regeneration post tonsillectomy using heparin binding epidermal growth factor like growth factor

Publications (1)

Publication Number Publication Date
CA2964378A1 true CA2964378A1 (en) 2016-04-28

Family

ID=55761476

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2964378A Abandoned CA2964378A1 (en) 2014-10-21 2015-10-21 Promoting epithelial regeneration post tonsillectomy using heparin binding epidermal growth factor like growth factor

Country Status (6)

Country Link
US (2) US20170232065A1 (https=)
EP (1) EP3209322A4 (https=)
JP (1) JP2017537067A (https=)
AU (2) AU2015336008B2 (https=)
CA (1) CA2964378A1 (https=)
WO (1) WO2016064998A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210138036A1 (en) * 2014-10-21 2021-05-13 The Board Of Trustees Of The Leland Stanford Junior University Method for Treating or Preventing Radiotherapy-and Chemotherapy-Associated Oral Mucositis Using Locally Administered Heparin Binding Epidermal Growth Factor Like Growth Factor (HB-EGF)
WO2019231860A1 (en) * 2018-05-27 2019-12-05 The Board Of Trustees Of The Leland Stanford Junior University Method for treating or preventing radiotherapy- and chemotherapy-associated oral mucositis using locally administered heparin binding epidermal growth factor like growth factor (hb-egf)
US11980613B2 (en) * 2018-07-12 2024-05-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for reversing HIV latency using BAF complex modulating compounds
WO2020243607A1 (en) * 2019-05-31 2020-12-03 The Board Of Trustees Of The Leland Stanford Junior University Mucoadhesive microgel compositions and methods for using the same
EP4247964A4 (en) * 2020-12-18 2025-07-23 Univ Duke COMPOSITIONS AND METHODS FOR ENHANCING SPINAL CORD TISSUE REGENERATION

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112620A (en) * 1990-09-20 1992-05-12 Mikkur, Inc. Polyethylene glycol ointment for apthous ulcers
ATE199095T1 (de) * 1990-10-16 2001-02-15 Childrens Medical Center Heparin bindendes mitogen mit homologie zum epidermis wachstumsfaktor (egf)
US6682501B1 (en) * 1996-02-23 2004-01-27 Gyrus Ent, L.L.C. Submucosal tonsillectomy apparatus and method
US8912165B2 (en) * 1999-03-12 2014-12-16 Biotec Pharmacon Asa Methods of skin treatment and use of water-soluble β-(1,3) glucans as active agents for producing therapeutic skin treatment agents
WO2007014167A2 (en) * 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions for and methods of treating epithelial diseases with growth factors
US20090089087A1 (en) * 2005-11-21 2009-04-02 Kevin Todd Kotecki Method for Developing and Marketing a Post Operative Home Recovery Kit for Use by a Patient After Discharge From a Hospital and for Recuperation At Home
KR20090042782A (ko) * 2006-07-10 2009-04-30 시네수스 인코포레이티드 부비동개구 복합체에 활성제를 방출하는 이식가능한 지속성약물 전달 장치
US8093213B2 (en) * 2007-04-30 2012-01-10 Nationwide Children's Hospital, Inc. Heparin binding epidermal growth factor (HB-EGF) for use in methods of treating and preventing intestinal injury related to hemorrhagic shock and resuscitation
EP2424448A4 (en) * 2009-04-27 2015-03-04 Intersect Ent Inc DEVICES AND METHODS FOR TREATING A PAIN ASSOCIATED WITH AMYGDALECTOMIES
US10058631B2 (en) * 2014-07-09 2018-08-28 Cook Medical Technologies Llc Tonsillectomy sponge
EP3573697A4 (en) * 2017-01-27 2020-11-11 The UAB Research Foundation PROLONGED INTRA-TONSILLARY DRUG ADMINISTRATION WITH NEEDLE NETWORK

Also Published As

Publication number Publication date
US20210038690A1 (en) 2021-02-11
WO2016064998A1 (en) 2016-04-28
JP2017537067A (ja) 2017-12-14
US20170232065A1 (en) 2017-08-17
EP3209322A1 (en) 2017-08-30
AU2019272030A1 (en) 2019-12-19
AU2015336008B2 (en) 2019-11-21
EP3209322A4 (en) 2018-07-18
AU2015336008A1 (en) 2017-05-25

Similar Documents

Publication Publication Date Title
US20210038690A1 (en) Promoting epithelial regeneration using heparin binding epidermal growth factor like growth factor
CN114671941B (zh) 神经生长因子突变体
KR20140084208A (ko) 정제된 인자 ｖｉｉｉ의 재구성 후의 안정성을 향상시키는 방법
US20250277010A1 (en) Agent for treatment of dermatological disorders
RU2426745C2 (ru) Рекомбинантный химерный белок фактора ингибирования нейтрофилов и гиругена и содержащая его фармацевтическая композиция
EP2618829A2 (en) Therapeutic applications of smad7
US7645735B2 (en) Anti-angiogenic peptides for treating or preventing endometriosis
EP4091621A1 (en) Method for treatment of nerve injury and related disease
US20210138036A1 (en) Method for Treating or Preventing Radiotherapy-and Chemotherapy-Associated Oral Mucositis Using Locally Administered Heparin Binding Epidermal Growth Factor Like Growth Factor (HB-EGF)
KR20230052929A (ko) 종양 치료 방법 및 약물
WO2019231860A1 (en) Method for treating or preventing radiotherapy- and chemotherapy-associated oral mucositis using locally administered heparin binding epidermal growth factor like growth factor (hb-egf)
WO2025043075A1 (en) Methods of treating myocardial infarction, ischemia, and ischemia reperfusion injury
CN105934250A (zh) 治疗脑内出血的组合物和方法
EP4613286A1 (en) Method for promoting pathological tdp-43 protein degradation, and drug
RU2799211C2 (ru) Средство для лечения дерматологических заболеваний
HK40131031A (en) Method for promoting pathological tdp-43 protein degradation, and drug
HK40047629B (zh) 皮肤病治疗剂
TW202228766A (zh) 一種治療神經損傷及其相關病症的方法
HK40047629A (zh) 皮肤病治疗剂
HK40084760A (en) Method for treatment of nerve injury and related disease
HK40040435A (en) Compositions and methods for treating intracerebral hemorrhage
HK1240129A1 (en) Method for preventing or treating diabetic retinopathy
HK1223294B (en) Therapeutic applications of smad7

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220112